Abstract
The absolute sensitivity signs of breast cancer to the drug have not yet been developed. Data from clinical trials on the study of experimental laboratory predictive markers of chemosensitivity: TOP2alpha (topoisomerase 2-alpha), beta-tubulin (subunit of dimeric protein tubulin), and BRCA1 (breast cancer 1) are contradictory and not numerous. Analysis of the results by the end of the clinical trial will allow examining the correlation between the effectiveness of preoperative taxane-chemotherapy and the level of experimental and standard molecular markets that is important for development of algorithm of treatment tactics for patients with locally advanced breast cancer.
Publication types
-
Clinical Trial, Phase III
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Antigens, Neoplasm / analysis
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / analysis*
-
Breast Neoplasms / chemistry
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology*
-
Breast Neoplasms / surgery
-
DNA Topoisomerases, Type II / analysis
-
DNA-Binding Proteins / analysis
-
Drug Administration Schedule
-
Female
-
Humans
-
Immunohistochemistry
-
Middle Aged
-
Neoplasm Staging
-
Preoperative Period
-
Taxoids / administration & dosage
-
Treatment Outcome
-
Tubulin / analysis
Substances
-
Antigens, Neoplasm
-
Biomarkers, Tumor
-
DNA-Binding Proteins
-
Taxoids
-
Tubulin
-
DNA Topoisomerases, Type II